- Home
- AIRS vs CLLS Comparison
AIRS vs CLLS Comparison
Compare AIRS & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- CLLS
- Stock Information
- Founded
- AIRS 2012
- CLLS 1999
- Country
- AIRS United States
- CLLS France
- Employees
- AIRS N/A
- CLLS N/A
- Industry
- AIRS Medical/Nursing Services
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- CLLS Health Care
- Exchange
- AIRS Nasdaq
- CLLS Nasdaq
- Market Cap
- AIRS 302.9M
- CLLS 240.2M
- IPO Year
- AIRS 2021
- CLLS 2007
- Fundamental
- Price
- AIRS $5.36
- CLLS $2.01
- Analyst Decision
- AIRS Hold
- CLLS Buy
- Analyst Count
- AIRS 2
- CLLS 2
- Target Price
- AIRS $5.50
- CLLS $8.00
- AVG Volume (30 Days)
- AIRS 129.5K
- CLLS 22.9K
- Earning Date
- AIRS 11-07-2024
- CLLS 11-04-2024
- Dividend Yield
- AIRS N/A
- CLLS N/A
- EPS Growth
- AIRS N/A
- CLLS N/A
- EPS
- AIRS N/A
- CLLS N/A
- Revenue
- AIRS $193,025,000.00
- CLLS $19,635,000.00
- Revenue This Year
- AIRS N/A
- CLLS $271.02
- Revenue Next Year
- AIRS $11.85
- CLLS $33.48
- P/E Ratio
- AIRS N/A
- CLLS N/A
- Revenue Growth
- AIRS 6.58
- CLLS N/A
- 52 Week Low
- AIRS $2.92
- CLLS $0.96
- 52 Week High
- AIRS $8.30
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- AIRS 58.88
- CLLS 41.74
- Support Level
- AIRS $4.62
- CLLS $1.95
- Resistance Level
- AIRS $5.40
- CLLS $2.06
- Average True Range (ATR)
- AIRS 0.45
- CLLS 0.10
- MACD
- AIRS -0.00
- CLLS -0.01
- Stochastic Oscillator
- AIRS 53.41
- CLLS 33.33
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.